NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Onco-Innovations Advances ONC010 Manufacturing with Nanosoft
Onco-Innovations Limited is advancing manufacturing development for its lead nanoparticle-formulated cancer therapy ONC010 through a collaboration with Nanosoft Polymers, focusing on scalable and reproducible polymer processes to support future clinical and regulatory milestones.
Onco-Innovations announced the initiation of polymer process development and analytical characterization activities by Nanosoft Polymers for ONC010, its lead nanoparticle-formulated Polynucleotide Kinase Phosphatase inhibitor.
The activities include polymer synthesis optimization, characterization methodology development, molecular weight assessment, purification strategy refinement, and manufacturing scalability assessments.
The goal is to establish a scalable, reproducible, and analytically characterized polymer platform to support future formulation, manufacturing, regulatory, and clinical development of ONC010.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. It has secured an exclusive worldwide license to patented technology targeting solid tumors.
ONC010 is Onco-Innovations’ lead nanoparticle-formulated Polynucleotide Kinase Phosphatase inhibitor, a potential cancer therapy.
Nanosoft’s expertise in polymer science and nanoparticle drug delivery is expected to strengthen the technical foundation of the ONC010 platform and support future GMP manufacturing readiness.
The full press release is available at https://nnw.fm/BeSoS.
The scalable and reproducible polymer platform being developed is intended to support future formulation, manufacturing, regulatory, and clinical development, thereby advancing ONC010 toward clinical trials and potential approval.